[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553229":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Shanghai Pharmaceuticals Holding Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SPH7854","EXPERIMENTAL",null,[13],"Drug: SPH7854",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","SPH7854： Orally, 50-3200mg",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Placebo：Orally；",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Qin Yu","CONTACT","0086-028-85501685","hxeyyb@126.com",[34],{"facility":35,"status":36,"city":37,"state":11,"zip":11,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"West China Second University Hospital, Sichuan University","RECRUITING","Chengdu","China",{"type":40,"coordinates":41},"Point",[42,43],104.06667,30.66667,{"lat":43,"lon":42},[46],{"name":29,"role":30,"phone":11,"phoneExt":11,"email":11},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100553229",false,"NCT06483373","A Clinical Study of SPH7854 Granules in Healthy Subjects.","A Single and Multiple Dose-escalation, and Food Effects of Phase I Clinical Study to Evaluate the Tolerability\u002FSafety\u002FPharmacokinetics of SPH7854 Granules in Healthy Subjects.","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent；\n2. Healthy volunteers;\n3. Before receiving the investigational drug, the examination results were normal or clinically insignificant;\n4. Subjects who have no fertility plan\u002Fsperm donation\u002Fegg donation plan and voluntarily take effective contraceptive measures, from signing the informed consent to the prescribed time after the last dosing.\n\nExclusion Criteria:\n\n1. Female subjects who are breastfeeding or have positive pregnancy results;\n2. Subjects with chronic, unstable, or recurrent disease or surgery history who are judged by the investigator to be ineligible before signing informed consent;\n3. Subjects suffering from allergic diseases or having a history of severe allergies;\n4. Subjects who took the drug or food prohibited by the protocol prior to the first dose;\n5. Subjects with evidence of infection who could not be enrolled according to the investigator's judgement;\n6. Other circumstances that meet the protocol exclusion criteria.",true,"ALL","18 Years","45 Years",{"count":60,"type":61},111,"ESTIMATED","INTERVENTIONAL",[64],"EARLY_PHASE1","To evaluate the safety of SPH7854 in healthy subjects.",[67],"Inflammatory Bowel Disease","2026-04-29",{"date":70,"type":71},"2026-05-05","ACTUAL",{"date":73,"type":71},"2024-05-28",{"date":75,"type":61},"2026-12-31",{"name":5,"class":6},1]